Lymphokine Patents (Class 424/85.1)
  • Patent number: 10722537
    Abstract: Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: July 28, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: David B. Masopust, Jr., Vaiva D. Vezys
  • Patent number: 10696725
    Abstract: The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: June 30, 2020
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk Kim, Young Jin Park, In Young Choi, Sung Youb Jung
  • Patent number: 10690677
    Abstract: Methods for identifying compounds that modulate cellular responses stimulated by IgE, which include providing an impedance-based system that monitors cell-substrate impedance of cells on a substrate; introducing cells to the substrate of the system; adding at least one test compound and IgE to the cells, wherein the at least one test compound is suspected of modulating cell responses stimulated by the IgE; adding an antigen to the cells; monitoring the cell-substrate impedance of cells on the substrate; and analyzing the cell-substrate impedance to evaluate whether the at least one test compound alters a cellular response to stimulation with the IgE.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: June 23, 2020
    Assignee: ACEA Biosciences, Inc.
    Inventors: Xiao Xu, Yama A. Abassi, Xiaobo Wang, Jiangbo Gan
  • Patent number: 10617689
    Abstract: The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies of diabetes and related disorders, based on compositions controlling the blood glucose level.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: April 14, 2020
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Rodolphe Hajj
  • Patent number: 10622675
    Abstract: A solvent useful for lithium batteries comprises a compound of Formula (I): (R1)(R2)(R3)Si—R4—O—C(O)—[(O—R5)n—(O—C(O)]m—O—R6—X1. Each of R1 and R2 independently is alkyl; R3 is alkyl, —X2—Si(R7)(R8)(R9), or —CH2—O—C(O)—O—R10; X1 is H or —Si(R11)(R12)(R13); each of R4 and R6 independently is alkylene; each R5 independently is C2 to C6 alkylene; each of R7, R8, R9, and R10 independently is alkyl; X2 is O or alkylene; each of R11 and R12 independently is alkyl; R13 is alkyl or —X3—Si(R14)(R15)(R16); each of R14, R15, and R16 independently is alkyl; X3 is O or alkylene; m is 0 or 1, and n is 1-3; and when m is 0 and R3 is alkyl, X1 is —Si(R11)(R12)(R13). Also described is a method for manufacturing a compound of Formula (II): (R17)(R18)(R19)Si—CH2—O—C(O)—O—R20 where each R17, R18, R19, and R20 is alkyl.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: April 14, 2020
    Assignee: UCHICAGO ARGONNE, LLC
    Inventors: Trevor L. Dzwiniel, Krzysztof Pupek, Gregory K. Krumdick
  • Patent number: 10610570
    Abstract: This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears). For example, methods and materials for using BMP-5 polypeptides to treat rotator cuff conditions as well as methods and materials for using inhibitors of SIRT6, SIRT7, and/or HDAC10 polypeptide expression or activity to treat rotator cuff conditions are provided.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: April 7, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Scott M. Riester, John W. Sperling, Andre J. van Wijnen
  • Patent number: 10611830
    Abstract: The present invention provides an antibody or antibody fragment for specifically recognizing and binding to an ED-B domain of fibronectin. The antibody or antibody fragment can be widely used for in vitro detection and in vivo location of the ED-B protein domain, as well as targeted therapy of tumors.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: April 7, 2020
    Assignee: HEFEI LIFEON PHARMACEUTICAL CO. LTD.
    Inventors: Junqiu Ji, Mei Zhang, Meihua Gao, Jun Chen
  • Patent number: 10583182
    Abstract: The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.
    Type: Grant
    Filed: February 11, 2018
    Date of Patent: March 10, 2020
    Inventor: Atsuo Ochi
  • Patent number: 10570206
    Abstract: The present invention relates in general to the field of TNF ligand family members. In more detail the present invention relates to polypeptides comprising at least three components A, each of which comprises the sequence of a TNF homology domain (THD) of a TNF ligand family member, or a functional derivative thereof, and comprising at least one component B consisting of a VL region and a VH region linked directly to each other with a linker sequence L which has a length of <12 amino acids. Furthermore, the present invention also relates to nucleic acids encoding such polypeptides and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: February 25, 2020
    Assignee: UNIVERSITAT STUTTGART
    Inventors: Klaus Pfizenmaier, Roland Kontermann, Martin Siegemund
  • Patent number: 10556009
    Abstract: The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity agent.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 11, 2020
    Assignee: GlaxoSmithKline Intellectual Property Management Limited
    Inventors: Angela Blake-Haskins, Tristan Marshall, Melissa D. Perkins, Kristin O'Berry
  • Patent number: 10555963
    Abstract: Disclosed is the use of a klotho protein or related compounds (especially KL1 or KL1 analogue) for treatment, and especially treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents.
    Type: Grant
    Filed: March 25, 2012
    Date of Patent: February 11, 2020
    Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Ido Wolf, Tamar Rubinek, Bella Kaufman, Lilach Abramovitch
  • Patent number: 10556963
    Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 11, 2020
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Tim Beaumont, Marijn Aletta Gillissen, Adrianus Quirinus Bakker, Mette Deborah Hazenberg, Martijn Kedde
  • Patent number: 10537915
    Abstract: An illustrative embodiment of a contaminant resistant structure includes a substrate having a substrate surface, at least one contaminant resistant material provided on the substrate surface and a hydrophobic or oleophobic, and alternatively, a hydrophilic or oleophilic material provided on at least a portion of the substrate surface.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: January 21, 2020
    Assignee: The Boeing Company
    Inventors: Shawn Park, John Belk
  • Patent number: 10532045
    Abstract: Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: January 14, 2020
    Assignee: Signpath Pharma, Inc.
    Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard
  • Patent number: 10521911
    Abstract: A method of reviewing neural scans includes receiving at least one landmark corresponding to an anatomical region. A plurality of images of tissue including the anatomical region is received and a neural network configured to differentiate between healthy tissue and unhealthy tissue within the anatomical region is generated. The neural network is generated by a machine learning process configured to receive the plurality of images of tissue and generate a plurality of weighting factors configured to differentiate between healthy tissue and unhealthy tissue. At least one patient image of tissue including the anatomical region is received and a determination is made by the neural network whether the at least one patient image of tissue includes healthy or unhealthy tissue.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: December 31, 2019
    Assignee: Siemens Healtchare GmbH
    Inventors: Benjamin L. Odry, Hasan Ertan Cetingul, Mariappan S. Nadar, Puneet Sharma, Shaohua Kevin Zhou, Dorin Comaniciu
  • Patent number: 10513549
    Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: December 24, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G Sagert
  • Patent number: 10487421
    Abstract: The present disclosure discloses reinforced electrospun fibrous membranes and preparation methods therefor. The reinforced electrospun fibrous membranes can include an electrospun fibrous membrane body and a plurality of reinforcing thread sets fixed to the electrospun fibrous membrane body through holes thereon, wherein any two of the plurality of reinforcing thread sets are parallel to each other; each of the reinforcing thread sets comprises a starting end and a terminal end, both being connected to an edge of the electrospun fibrous membrane body; each of the reinforcing thread sets comprises at least one reinforcing fibrous thread consisting of a main thread and an auxiliary thread respectively arranged at a front side and a bottom side of the electrospun fibrous membrane body and configured to interlace each other at the through hole.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: November 26, 2019
    Assignee: Medprin Regenerative Medical Technologies Co., Ltd.
    Inventors: Guangyao Li, Kunxue Deng, Yaya Yang, Yuyu Yuan
  • Patent number: 10471110
    Abstract: This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction, dilated cardiomyopathy, inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditis), and congestive heart failure.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: November 12, 2019
    Assignee: DuPont Nutrition Biosciences ApS
    Inventors: Lotta Stenman, Sampo Lahtinen, John Konhilas
  • Patent number: 10463598
    Abstract: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: November 5, 2019
    Assignee: Averitas Pharma Inc.
    Inventors: Arturo J. Angel, Larry W. Litle, Keith R. Bley, Allan L. Wilcox, Gene C. Jamieson, Naweed Muhammad
  • Patent number: 10464982
    Abstract: This disclosure relates to recombinant proteins comprising a GM-CSF sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises N-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: November 5, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Andrea Pennati
  • Patent number: 10456451
    Abstract: The present invention features mutant stromal cell derived factor-1 (SDF-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase IV (DPPIV), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, cathepsin G, carboxypeptidase M, and carboxypeptidase N, but which retain chemoattractant activity.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 29, 2019
    Assignee: Mesoblast International Sàrl
    Inventors: Vincent Frans Maria Segers, Anthony Sandrasagra, Yan Qiu
  • Patent number: 10434188
    Abstract: The present invention provides fusion proteins including a hyaluronic acid-binding domain of a cartilage matrix protein and a conserved region of a growth factor protein. Certain embodiments provide nucleic nucleic acid sequences encoding a fusion protein and compositions thereof. Methods for using fusion polypeptides and nucleic acid molecules discloses herein are also provided. In certain embodiments, the fusion proteins and/or nucleic acid molecules can be used to treat a cartilage matrix protein-related condition in a subject.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: October 8, 2019
    Assignees: THE TRUSTEES OF INDIANA UNIVERSITY, UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Stephen B. Trippel, Shuiliang Shi
  • Patent number: 10426800
    Abstract: The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: October 1, 2019
    Assignee: CELL4VET CORPORATION
    Inventors: Ching Shwun Lin, Tom F. Lue, Guiting Lin
  • Patent number: 10421796
    Abstract: Lysine-depleted variants of fragment crystallizable (Fc) regions of immunoglobulins are disclosed. Also disclosed are fusion proteins comprised of N-terminal targeting or active peptide domains fused with such lysine-depleted variant IgG-Fc domains. Polynucleotides encoding such proteins, compositions and kits containing such proteins, and methods of using such proteins are also disclosed.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: September 24, 2019
    Inventor: Gray D Shaw
  • Patent number: 10420744
    Abstract: The present invention is directed compositions derived from green coffee bean extract and methods for the use and manufacture of such compositions. The compositions of the invention have unique ratios of chlorogenic acids which offer a therapeutic effect in the treatment of a variety of conditions and disorders. Methods for using the compositions of the invention include, but are not limited to, methods for treating obesity and methods for regulating serum lipids.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: September 24, 2019
    Assignee: Vidya Herbs, Inc.
    Inventors: Kodimule Shyam Prasad, Harakanahalli Lingaraju Basavegowda
  • Patent number: 10398772
    Abstract: Compositions including a therapeutically effective amount of an HIV immunogen in combination with an agent that stimulates the Ras pathway, wherein the agent is not an aluminum salt, are disclosed. Methods are also disclosed for inducing an immune response to HIV, and/or to inhibit or treat HIV infection, in a subject, using an HIV immunogen and an agent that stimulates the Ras pathway. Methods also are disclosed for determining if an immunogenic composition will induce a protective response, and/or to determine if an immunogenic composition is of use to prevent or treat an HIV infection. The methods including determining if the immunogenic composition increases the level of one or more components of the Ras signaling pathway.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: September 3, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Oregon Health & Science University
    Inventors: Genoveffa Franchini, Rafick-Pierre Sekaly, Slim Fourati, Mark Cameron, Monica Vaccari, Luca Schifanella, Shari Gordon, Melvin Doster, Namal Malimbada Liyanage
  • Patent number: 10400242
    Abstract: Compositions and methods for treating acute myeloid leukemia (AML) based on upregulating expression of microRNA-22 (miR-22), and a nanoparticle delivery system that utilizes FLT3-functionalized polyamidoamine (PAMAM) dendromirs for targeted delivery of miR-22 and/or agents that upregulate expression of miR-22 to AML cells.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: September 3, 2019
    Assignee: University of Cincinnati
    Inventors: Jianjun Chen, Xi Jiang
  • Patent number: 10371705
    Abstract: The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: August 6, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Douglas B. Cines, Zheng Cai, Zhiqiang Zhu
  • Patent number: 10363295
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: July 30, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Patent number: 10357545
    Abstract: Methods of treating subjects having a disease or disorder responsive to IL-10, including methods of administration and dosing regimens associated therewith, are provided.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: July 23, 2019
    Assignee: Armo Biosciences, Inc.
    Inventor: Martin Oft
  • Patent number: 10335458
    Abstract: Provided herein is a pharmaceutical composition for treating, preventing or ameliorating a bone or cartilage condition and methods of making and using the same.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: July 2, 2019
    Assignee: The Regents of the University of California
    Inventors: Chia Soo, Kang Ting, Shunichi Kuroda, Benjamin M. Wu
  • Patent number: 10322109
    Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: June 18, 2019
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Sadasivan Vidyasagar, Paul Okunieff, Lurong Zhang
  • Patent number: 10314882
    Abstract: The present disclosure provides methods and uses of Tie2 agonists alone or in combination with antiviral agents. In particular, the present disclosure provides methods and uses for treating influenza, treating a bacterial superinfection associated with influenza and decreasing lung endothelial leakage. The disclosure also provides compositions comprising (a) a Tie2 agonist and (b) an antiviral agent and methods and uses thereof.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: June 11, 2019
    Assignees: Sunnybrook Research Institute, Unity Health Toronto
    Inventors: Daniel Dumont, Paul Van Slyke, Warren Lee
  • Patent number: 10293034
    Abstract: Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate 20, and methionine and optionally isoleucine. Employing, instead of the animal-derived protein albumin or gelatin, a combination of polysorbate 20 and methionine and optionally isoleucine as botulinum toxin stabilizers, the liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients. Superior to conventional compositions employing either detergents or amino acids in terms of the storage stability of botulinum toxin at 25˜37° C. as well as at refrigerated temperatures, the liquid pharmaceutical composition of the present invention is very useful for storing botulinum toxin under an emergency condition such as an environment without maintaining low temperature.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 21, 2019
    Assignee: Medy-Tox, Inc.
    Inventors: Hyun Ho Jung, Gi Hyeok Yang, Hack Woo Kim, Hee Dong Woo, Chang Hoon Rhee
  • Patent number: 10265412
    Abstract: The present invention relates in general to the field of enzyme replacement therapy, and specifically to chimeric proteins including protein hormone-therapeutic protein conjugates and fusion proteins, wherein the protein hormone is selected from a protein hormone which is able to cross the blood brain barrier, for the treatment of lysosomal storage diseases, compositions of the same and to methods of use thereof.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: April 23, 2019
    Assignees: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science, The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
    Inventors: Naftali Stern, Ruth Navon, Anthony Futerman, Ari Zimran, Etty Osher
  • Patent number: 10245281
    Abstract: Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: April 2, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Simon Cool, Victor Nurcombe
  • Patent number: 10183093
    Abstract: A wound dressing composition comprising a non-viable cell lysate or releasate derived from a hepatocyte cell or an inflammatory cell such as a macrophage. Also provided are wound dressings comprising such compositions, methods of making such compositions, and the use of such compositions for the treatment of wounds.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: January 22, 2019
    Assignee: KCI USA, INC.
    Inventors: Rachael Louise McInnes, Breda Mary Cullen, Lindsay Page
  • Patent number: 10180433
    Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: January 15, 2019
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steve Roffler, Wen-Wei Lin, I-Ju Chen
  • Patent number: 10137109
    Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 27, 2018
    Assignee: INCURON, INC.
    Inventors: John Tucker, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
  • Patent number: 10123985
    Abstract: Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: November 13, 2018
    Assignees: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Howard Hughes Medical Institute
    Inventors: David M. Sabatini, Kivanc Birsoy, Matthew George Vander Heiden, Lucas Bryan Sullivan, Dan Yi Gui
  • Patent number: 10092597
    Abstract: Graft-versus-host disease (GVHD) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control GVHD may cause general immune suppression and limit the effectiveness of allograft transplantation. Adoptive transfer of regulatory T cells (Treg) can prevent GVHD in rodents, indicating the therapeutic potential of Treg for GVHD in humans. However, the clinical application of Treg-based therapy is hampered by the low frequency of human Treg and the lack of a reliable model to test their therapeutic effects in vivo. Human alloantigen-specific Treg are generated from antigenically-naïve precursors in a large scale ex vivo using allogeneic activated B cells as stimulators. Here, a human allogeneic GVHD model is established in humanized mice to mimic GVHD after allograft transplantation in humans.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: October 9, 2018
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventors: Wenwei Tu, Yinping Liu, Jian Zheng
  • Patent number: 10071158
    Abstract: The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one glucocorticoid.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: September 11, 2018
    Assignee: LINDIS BIOTECH GMBH
    Inventors: Markus M. Heiss, Horst Lindhofer
  • Patent number: 10036752
    Abstract: The invention provides a method of determining the colorectal cancer status of subject, comprising applying to a colon and/or rectal surface an agent which is able to distinguish between a) mature glycosylated forms of MUC2 and b) incomplete or aberrant glycosylated forms of MUC2, and determining the extent to which the agent binds.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: July 31, 2018
    Assignee: Oxford University Innovation Limited
    Inventor: Trevor Ming-Yee Yeung
  • Patent number: 10028951
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: July 24, 2018
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Zhigang Xiong, Roger P. Simon
  • Patent number: 10016524
    Abstract: The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: July 10, 2018
    Assignees: President and Fellows of Harvard College, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Cathal J. Kearney, Uyanga Tsedev, David J. Mooney, Aristidis Veves, Thomas Michael Braschler, Sidi A. Bencherif
  • Patent number: 10016416
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: July 10, 2018
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Zhigang Xiong, Roger P. Simon
  • Patent number: 9990716
    Abstract: In a method for visualization of scar tissue in medical imaging data of a heart, medical imaging data representing a heart myocardium and scar tissue within the heart myocardium are obtained and provided to a computer. The computer deviates the thickness of the myocardium into a number of layers and calculates the presence and distribution of scar tissue within each of the layers. The scar tissue is shown in a visualization of the myocardium; and a user is provided with controls to allow the user to select which of the layers of scar tissue is visualised.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: June 5, 2018
    Assignee: Siemens Healthcare GmbH
    Inventors: Peter Mountney, Sabrina Reiml, Daniel Toth, Alexander Brost, Maria Panayiotou, Kawal Rhode
  • Patent number: 9974288
    Abstract: The present invention provides to a polyethylene glycol-modified feline-derived protein which is obtained by chemically modifying a feline-derived protein with polyethylene glycol. The feline-derived protein is produced by a method comprising any or a combination of extracting the protein from somatic cells of a transgenic bird and/or an egg laid thereby, purifying and activating the same. The transgenic bird has a foreign gene containing a sequence encoding a feline-derived protein.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: May 22, 2018
    Assignee: Kaneka Corporation
    Inventors: Tomoyuki Nakaishi, Takuya Shindo, Tomoko Awa
  • Patent number: 9976147
    Abstract: Described herein, inter alia, are STAT-binding nucleic acids-including compositions and methods of using the same.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: May 22, 2018
    Assignee: City of Hope
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski
  • Patent number: 9950014
    Abstract: Methods for treating or preventing preeclampsia or eclampsia by administering adherent stromal cells are described. The adherent stromal cells may be derived from bone marrow, placenta, or adipose tissue. Also described is the use of adherent stromal cells for the manufacture of a medicament, and an article of manufacture comprising a packaging material which comprises a label for use in treating or preventing preeclampsia or eclampsia.
    Type: Grant
    Filed: August 31, 2013
    Date of Patent: April 24, 2018
    Assignee: PLURISTEM LTD.
    Inventors: Ayelet Chajut, Eytan Abraham